A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy

Bell, Erica H.; Kirste, Simon; Fleming, Jessica L.; Stegmaier, Petra; Drendel, Vanessa; Mo, Xiaokui; Ling, Stella; Fabian, Denise; Manring, Isabel; Jilg, Cordula A.; Schultze-Seemann, Wolfgang; McNulty, Maureen; Zynger, Debra L.; Martin, Douglas D.; White, Julia; Werner, Martin; Grosu, Anca L.; Chakravarti, Arnab

doi:10.1371/journal.pone.0118745

Cited by 27 publications

(27 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a predictive model for BCR that focused on miRNAs that are potentially predictive for patients who received salvage RT was reported [48]. Besides confirming previous data depicting an 88-miRNA signature, which could distinguish early from late biochemical failure patients, they identified nine miRNAs associated with BCR after salvage RT, and three of them were completely new (miR-1193, miR-4516, and miR-626).…”

Section: Evidence Synthesissupporting

confidence: 64%

The Potential of MicroRNAs as Prostate Cancer Biomarkers

et al. 2016

View full text Add to dashboard Cite

Context Short noncoding RNAs known as microRNAs (miRNAs) control protein expression through the degradation of RNA or the inhibition of protein translation. The miRNAs influence a wide range of biologic processes and are often deregulated in cancer. This family of small RNAs constitutes potentially valuable markers for the diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients, as well as potential drugs (miRNA mimics) or drug targets (anti-miRNAs) in PCa management. Objective To review the currently available data on miRNAs as biomarkers in PCa and as possible tools for early detection and prognosis. Evidence acquisition A systematic review was performed searching the PubMed database for articles in English using a combination of the following terms: microRNA, miRNA, cancer, prostate cancer, miRNA profiling, diagnosis, prognosis, therapy response, and predictive marker. Evidence synthesis We summarize the existing literature regarding the profiling of miRNA in PCa detection, prognosis, and response to therapy. The articles were reviewed with the main goal of finding a common recommendation that could be translated from bench to bedside in future clinical practice. Conclusions The miRNAs are important regulators of biologic processes in PCa progression. A common expression profile characterizing each tumor subtype and stage has still not been identified for PCa, probably due to molecular heterogeneity as well as differences in study design and patient selection. Large-scale studies that should provide additional important information are still missing. Further studies, based on common clinical parameters and guidelines, are necessary to validate the translational potential of miRNAs in PCa clinical management. Such common signatures are promising in the field and emerge as potential biomarkers. Patient summary The literature shows that microRNAs hold potential as novel biomarkers that could aid prostate cancer management, but additional studies with larger patient cohorts and common guidelines are necessary before clinical implementation.

show abstract

Section: Evidence Synthesissupporting

confidence: 64%

The Potential of MicroRNAs as Prostate Cancer Biomarkers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Conversely, no data have been thus far reported in thyroid tumors for miR-148b, miR-1285-5p and miR-4516, although deregulation of these miRNAs is associated with other cancer types. [50][51][52][53][54] Taken together, our data suggest that evaluating miR-146-5p, miR-199a, miR199b, miR-1285-5p, miR-1915-3p, miR-4516, and miR-148b could be a useful diagnostic tool for differentiating between encapsulated tumors and other more aggressive entities.…”

Section: Discussionmentioning

confidence: 79%

miRNA expression profiling of ‘noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas

et al. 2017

View full text Add to dashboard Cite

Follicular variants of papillary thyroid carcinoma include encapsulated (with or without capsular/vascular invasion) and infiltrative forms, which have different clinical behaviors. The encapsulated forms that lack capsular invasion have an indolent clinical behavior that is similar to benign lesions; therefore, they were recently reclassified as 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' (NIFTPs). Because NIFTPs have nuclear features of papillary carcinomas, distinguishing between NIFTPs and infiltrative follicular variant of papillary thyroid carcinoma is almost impossible with cytological examination. The aim of this study is to determine whether miRNA expression profiles may help distinguish between NIFTPs versus follicular adenomas and infiltrative follicular variant of papillary thyroid carcinomas. The expression profiling of 798 miRNAs was tested in 54 thyroid tumors, including 18 follicular adenomas, 19 NIFTPs and 17 infiltrative follicular variant of papillary thyroid carcinomas, using nCounter Nanostring. We found that miR-146-5p, miR-221-5p, miR-222-3p, miR-30e-3p, and miR-152-3p could discriminate between benign and malignant lesions with a very high level of significance (P-value<0.001). High expression levels of miR-146-5p, miR-199a-5p, miR-199b-5p, miR-1285-5p, miR-1915-3p, and miR-4516, and low miR-148b-3p expression were associated with infiltrative growth of follicular variant of papillary thyroid carcinomas. Interestingly, miR-152-3p, miR-185-5p, and miR-574-3p were significantly downregulated in NIFTPs compared with follicular adenomas, whereas miR-10a-5p and miR-320e can discriminate between NIFTPs and infiltrative forms of follicular variant of papillary thyroid carcinomas. In conclusion, a panel of these markers could have high diagnostic potential as well as could be applied to presurgical fine-needle aspiration, especially for lesions classified as indeterminate thyroid nodules.

show abstract

“…Of the 3 miRNAs included in our validated prognostic classifier, only miR-221 has previously been included in prognostic miRNA signatures for PC, but the earlier studies all lacked independent validation and/or multivariate analysis [ 20 , 21 , 29 ]. One of the studies [ 21 ] presented a model called miQ (miR-96-5p, miR-183-5p, miR-145-5p, and miR-221-5p) that distinguished aggressive from non-aggressive PC in a training set ( n = 49) and was validated using data from Taylor et al [ 16 , 17 ], as also used here.…”

Section: Discussionmentioning

confidence: 99%

Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling

Kristensen

Thomsen²,

Haldrup

et al. 2016

Oncotarget

View full text Add to dashboard Cite

PurposeThis study investigates the diagnostic and prognostic biomarker potential of miRNAs in prostate cancer (PC).ResultsWe identified several new deregulated miRNAs between non-malignant (NM) and PC tissue samples and between more/less aggressive PC subgroups. We also developed and validated a novel 13-miRNA diagnostic classifier with high sensitivity and specificity for PC. Finally, we trained a new 3-miRNA prognostic classifier (miR-185-5p+miR-221-3p+miR-326) that predicted time to biochemical recurrence (BCR) independently of routine clinicopathological variables in a training radical prostatectomy (RP) cohort (n = 126) as well as in two independent validation cohorts (n = 110 and n = 99).Experimental DesignAfter RT-qPCR-based profiling of 752 miRNAs in 13 NM and 134 PC tissue samples (cohort 1), we selected 93 top candidate diagnostic/prognostic miRNAs for validation in two independent patient sets (cohort 2: 19 NM and 138 PC; cohort 3: 28 NM and 113 PC samples). Diagnostic potential was assessed by ROC curve analysis and prognostic potential by Kaplan-Meier, uni- and multivariate Cox regression analyses. BCR after RP was used as endpoint.ConclusionsThis is the first report of a miRNA signature with significant independent prognostic value demonstrated in three PC patient cohorts.

show abstract

A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy

Cited by 27 publications

References 86 publications

The Potential of MicroRNAs as Prostate Cancer Biomarkers

The Potential of MicroRNAs as Prostate Cancer Biomarkers

miRNA expression profiling of ‘noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas

Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling

Contact Info

Product

Resources

About